Literature DB >> 8384820

Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon.

G E Kleter1, J T Brouwer, R A Heijtink, S W Schalm, W G Quint.   

Abstract

In 24 patients with hepatitic C virus (HCV) infection who participated in a randomized trial with alpha 2B interferon, HCV RNA analysis by the polymerase chain reaction with two separate primer sets was performed at weeks 0, 4, and 24 and during a follow-up period of 6 to 9 months. Prior to therapy all patients were HCV RNA positive. During therapy, HCV RNA decreased to an undetectable level (< 1 chimpanzee infectious dose per ml) in nine patients at week 4. After week 4, no additional cases of HCV RNA disappearance (< 1 chimpanzee infectious dose per ml) were observed. During follow-up, HCV RNA could not be detected in four of the six patients with a sustained alanine aminotransferase response. These results suggest the probable predictive value of HCV RNA levels for detecting the failure of therapy in an early stage of HCV infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384820      PMCID: PMC187712          DOI: 10.1128/AAC.37.3.595

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

2.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

3.  The putative nucleocapsid and envelope protein genes of hepatitis C virus determined by comparison of the nucleotide sequences of two isolates derived from an experimentally infected chimpanzee and healthy human carriers.

Authors:  K Takeuchi; Y Kubo; S Boonmar; Y Watanabe; T Katayama; Q L Choo; G Kuo; M Houghton; I Saito; T Miyamura
Journal:  J Gen Virol       Date:  1990-12       Impact factor: 3.891

4.  The 5'-terminal sequence of the hepatitis C virus genome.

Authors:  H Okamoto; S Okada; Y Sugiyama; S Yotsumoto; T Tanaka; H Yoshizawa; F Tsuda; Y Miyakawa; M Mayumi
Journal:  Jpn J Exp Med       Date:  1990-06

5.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.

Authors:  N Kato; M Hijikata; Y Ootsuyama; M Nakagawa; S Ohkoshi; T Sugimura; K Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

6.  A cDNA clone closely associated with non-A, non-B hepatitis.

Authors:  M Maéno; K Kaminaka; H Sugimoto; M Esumi; N Hayashi; K Komatsu; K Abe; S Sekiguchi; M Yano; K Mizuno
Journal:  Nucleic Acids Res       Date:  1990-05-11       Impact factor: 16.971

7.  Structure and organization of the hepatitis C virus genome isolated from human carriers.

Authors:  A Takamizawa; C Mori; I Fuke; S Manabe; S Murakami; J Fujita; E Onishi; T Andoh; I Yoshida; H Okayama
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

8.  Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France.

Authors:  P Marcellin; N Boyer; E Giostra; C Degott; A M Courouce; F Degos; H Coppere; P Cales; P Couzigou; J P Benhamou
Journal:  Hepatology       Date:  1991-03       Impact factor: 17.425

9.  High doses of recombinant alpha-interferon or gamma-interferon for chronic hepatitis C: a randomized, controlled trial.

Authors:  F Sáez-Royuela; J C Porres; A Moreno; I Castillo; G Martinez; F Galiana; V Carreño
Journal:  Hepatology       Date:  1991-02       Impact factor: 17.425

10.  Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis.

Authors:  M R Jacyna; M G Brooks; R H Loke; J Main; I M Murray-Lyon; H C Thomas
Journal:  BMJ       Date:  1989-01-14
View more
  6 in total

1.  Strengths and limitations of commercial tests for hepatitis C virus RNA quantification.

Authors:  Chihiro Morishima; Minjun Chung; Ka Wing Ng; Donald J Brambilla; David R Gretch
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

2.  Hepatitis C: Recent advances.

Authors:  S D Shafran; J M Conly
Journal:  Can J Infect Dis       Date:  1993-07

3.  Modeling therapeutic benefit in the midst of uncertainty: therapy for hepatitis C.

Authors:  W G Bennett; S G Pauker; G L Davis; J B Wong
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

Review 4.  The clinical virology of hepatitis C virus.

Authors:  W L Irving
Journal:  Int J Exp Pathol       Date:  1994-04       Impact factor: 1.925

5.  Treatment of chronic hepatitis C with amantadine.

Authors:  J P Smith
Journal:  Dig Dis Sci       Date:  1997-08       Impact factor: 3.199

6.  Sequence analysis of the 5' untranslated region in isolates of at least four genotypes of hepatitis C virus in The Netherlands.

Authors:  G E Kleter; L J van Doorn; J T Brouwer; S W Schalm; R A Heijtink; W G Quint
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.